← Leaderboards
Edward David Ball
University Of California San Diego
$3,666,897
Attributed
$3,666,897
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $490.2K · FY2005–11$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$3,666,897 · 8
By mechanism
U01$1,688,781 · 1
R01$1,343,080 · 2
R21$631,558 · 1
R13$2,000 · 1
M01$1,478 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Laura S Redwine$5,363,609
- Asad Bashey$1,069,772
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical TrialsClinical ResearchInfectionNeoplasm /Cancer ImmunotherapyToxic EffectResourcesTransplantationReconstitutionImmuneHematopoietic Stem CellsFundingComplexSourceAcute Myelogenous LeukemiaGraft-Vs-Host DiseaseAllogenicBloodHematopoietic Stem Cell TransplantationRelapseMonoclonal AntibodyLeukocyte Activation /TransformationHuman Therapy EvaluationComplement
Grant awards (30)
Adoptive T-Cell Therapy for Acute Leukemia$310,970
R21 · FY2011 · CA · contact PI
Adoptive T-Cell Therapy for Acute Leukemia$320,588
R21 · FY2010 · CA · contact PI
CTLA-4 Blockade to Stimulate Allogeneic Graft vs Tumor$169,262
U01 · FY2010 · HL · contact PI
CLINICAL TRIAL: RITUXAN/BEAM VS BEXXAR/BEAM FOR DIFFUSE LARGE B CELL NON-HODGKI$345
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: RITUXAN/BEAM VS BEXXAR/BEAM FOR DIFFUSE LARGE B CELL NON-HODGKI$1,133
M01 · FY2009 · RR · contact PI
CTLA-4 Blockade to Stimulate Allogeneic Graft vs Tumor$1
U01 · FY2009 · HL · contact PI
CTLA-4 Blockade to Stimulate Allogeneic Graft vs Tumor$1
U01 · FY2008 · HL · contact PI
CTLA-4 Blockade to Stimulate Allogeneic Graft vs Tumor$1
U01 · FY2007 · HL · contact PI
CTLA-4 Blockade to Stimulate Allogeneic Graft vs Tumor$154,880
U01 · FY2006 · HL · contact PI
CTLA-4 Blockade in Allo Stem Cell Transplantation$286,259
R01 · FY2005 · CA
CTLA-4 Blockade to Stimulate Allogeneic Graft vs tumor$1
U01 · FY2005 · HL
CTLA-4 Blockade to Stimulate Allogeneic Graft vs tumor$405,001
U01 · FY2004 · HL
Monoclonal Antibody for Treatment of Leukemia$239,400
R01 · FY2004 · CA
CTLA-4 Blockade to Stimulate Allogeneic Graft vs tumor$405,000
U01 · FY2003 · HL
Monoclonal Antibody for Treatment of Leukemia$239,400
R01 · FY2003 · CA
Symposium- Advances in Stem Cell Transplantation$2,000
R13 · FY2003 · CA
Monoclonal Antibody for Treatment of Leukemia$239,400
R01 · FY2002 · CA
CTLA-4 Blockade to Stimulate Allogeneic Graft vs tumor$149,696
U01 · FY2002 · HL
ANTIBODY THERAPY IN RELAPSED ACUTE MYELOID LEUKEMIA$0
M01 · FY2002 · RR
ANTIBODY THERAPY IN RELAPSED ACUTE MYELOID LEUKEMIA$0
M01 · FY2002 · RR
ANTIBODY THERAPY IN RELAPSED ACUTE MYELOID LEUKEMIA$0
M01 · FY2002 · RR
ANTIBODY THERAPY IN RELAPSED ACUTE MYELOID LEUKEMIA$0
M01 · FY2002 · RR
CTLA-4 Blockade to Stimulate Allogeneic Graft vs tumor$404,938
U01 · FY2001 · HL
Monoclonal Antibody for Treatment of Leukemia$239,400
R01 · FY2001 · CA
MONOCLONAL ANTIBODIES FOR THE TREATMENT OF LEUKEMIA$99,221
R01 · FY2001 · CA
ANTIBODY THERAPY IN RELAPSED ACUTE MYELOID LEUKEMIA$0
M01 · FY2001 · RR
ANTIBODY THERAPY IN RELAPSED ACUTE MYELOID LEUKEMIA$0
M01 · FY2001 · RR
ANTIBODY THERAPY IN RELAPSED ACUTE MYELOID LEUKEMIA$0
M01 · FY2000 · RR
ANTIBODY THERAPY IN RELAPSED ACUTE MYELOID LEUKEMIA$0
M01 · FY2000 · RR
ANTIBODY THERAPY IN RELAPSED ACUTE MYELOID LEUKEMIA$0
M01 · FY2000 · RR